News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

ORION-10 A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Study Status:

Active, Not recruiting

Contact Information:

(956) 362-2378

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The purpose is to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s) in patients with atherosclerotic cardiovascular disease and elevated LDL – C (Bad Cholesterol)

Information: 

Principal Investigator
Mahesh Changlani, MD
Co-PI
John Rodriguez
Sponsor
The Medicines Comapany
Type of Trial
Interventional
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram